XML 19 R6.htm IDEA: XBRL DOCUMENT v3.3.1.900
Consolidated Statement of Stockholders' Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Secure DNA
Mandiant, Inc.
nPulse Technologies
Additional Paid-In Capital
Additional Paid-In Capital
Secure DNA
Additional Paid-In Capital
Mandiant, Inc.
Additional Paid-In Capital
nPulse Technologies
Notes Receivable from Stockholders
Accumulated Other Comprehensive Loss
Accumulated Deficit
Treasury Stock
Convertible Preferred Stock
Common Stock
Common Stock
Secure DNA
Common Stock
Mandiant, Inc.
Common Stock
nPulse Technologies
Beginning balance, value at Dec. 31, 2012 $ 5,390       $ 109,252       $ (1,003) $ 0 $ (102,867)   $ 6 $ 2      
Beginning balance (in shares) at Dec. 31, 2012                         64,115 22,435      
Issuance of common stock 320,979       320,977                 $ 2      
Issuance of common stock (in shares)                           17,450      
Conversion of convertible preferred stock to common stock in connection with initial public offering 0       (1)               $ (6) $ 7      
Conversion of convertible preferred stock to common stock in connection with initial public offering (in shares)                         (64,590) 74,222      
Conversion of preferred stock warrant to common stock warrant in connection with initial public offering 10,067       10,067                        
Issuance of common stock for equity awards, net of repurchases 2,394       2,393                 $ 1      
Issuance of common stock for equity awards, net of repurchases (in shares)                           6,680      
Issuance of common stock related to acquisitions 791,917 $ 800 $ 791,117     $ 800 $ 791,115                 $ 2  
Issuance of common stock related to acquisitions (in shares)                             50 16,921  
Payment of note receivable from stockholder, net of early exercises 1,831       828       1,003                
Net proceeds from issuance of Series F convertible preferred stock 4,994       4,994                        
Net proceeds from issuance of Series F convertible preferred stock (in shares)                         475        
Vesting of early exercise of equity awards 2,307       2,307                        
Stock-based compensation 28,858       28,858                        
Net loss (120,635)                   (120,635)            
Ending balance, value at Dec. 31, 2013 1,048,102       1,271,590       0 0 (223,502)   $ 0 $ 14      
Ending balance (in shares) at Dec. 31, 2013                         0 137,758      
Issuance of common stock 444,295       444,295                        
Issuance of common stock (in shares)                           5,582      
Issuance of common stock for equity awards, net of repurchases 20,659       20,658                 $ 1      
Issuance of common stock for equity awards, net of repurchases (in shares)                           8,030      
Issuance of common stock related to acquisitions 1,398     $ 1,398       $ 1,398                  
Issuance of common stock related to acquisitions (in shares)                                 296
Issuance of common stock related to employee stock purchase plan     21,228       21,228                    
Issuance of common stock related to employee stock purchase plan (in shares)                           1,194      
Assumption of vested options related acquisition     $ 3,135       $ 3,135                    
Vesting of early exercise of equity awards 4,390       4,390                        
Stock-based compensation 151,852       151,852                        
Unrealized loss on investments (441)                 (441)              
Net loss (443,790)                   (443,790)            
Ending balance, value at Dec. 31, 2014 1,250,828       1,918,546       0 (441) (667,292)   $ 0 $ 15      
Ending balance (in shares) at Dec. 31, 2014                         0 152,860      
Issuance of common stock for equity awards, net of repurchases 27,063       27,062                 $ 1      
Issuance of common stock for equity awards, net of repurchases (in shares)                           7,786      
Issuance of common stock related to acquisitions 0     $ 210,401       $ 210,401                  
Issuance of common stock related to employee stock purchase plan 21,880       21,880                        
Excess tax benefit on vesting of awards and options exercised 809       809                        
Issuance of common stock related to employee stock purchase plan (in shares)                           997      
Prepaid forward stock purchase (150,000)                     $ (150,000)          
Vesting of early exercise of equity awards 2,271       2,271                        
Stock-based compensation 222,119       222,119                        
Unrealized loss on investments (1,784)                 (1,784)              
Net loss (539,215)                   (539,215)            
Ending balance, value at Dec. 31, 2015 $ 1,044,372       $ 2,403,088       $ 0 $ (2,225) $ (1,206,507) $ (150,000) $ 0 $ 16      
Ending balance (in shares) at Dec. 31, 2015                         0 161,643